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Abstract Previous studies report conflicting data on
outcomes of pregnancy-associated breast cancer (PABC).
Our aim was to examine the effect of a postpartum diag-
nosis on maternal prognosis in a young women’s breast
cancer cohort. We conducted a retrospective cohort study
of women age B45 years, diagnosed with breast cancer
(n = 619) during 1981–2011 at the University of Colorado
Hospital and The Shaw Cancer Center in Edwards, CO.
Breast cancer cases were grouped according to time
between giving birth and diagnosis: nulliparous (n = 125),
pregnant (n = 24), \ 5 years postpartum (n = 136), [5—
\10 postpartum (n = 130), and C10 years postpartum
(n = 147), to examine the clinicopathologic features and
the risk of distance recurrence and death. Cases diagnosed
after pregnancy, but within five-years postpartum, had an
approximate three fold increased risk of distant recurrence
(HR 2.80, 95 % CI: 1.12–6.57) and death (HR 2.65, 95 %
CI: 1.09–6.42) compared to nulliparous cases. Postpartum
cases diagnosed within five years of last childbirth dem-
onstrated a higher five-year distant recurrence probability
(31.1 %) and a markedly lower five-year overall survival
probability (65.8 %) compared to nulliparous cases (14.8
and 98.0 %, respectively). A diagnosis of breast cancer
during the first five-years postpartum confers poorer
maternal prognoses after adjustment for biologic subtype,
stage, and year of diagnosis. We propose that the definition
of PABC should include cases diagnosed up to at least five-
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years postpartum to better delineate the increased risk
imparted by a postpartum diagnosis. Based on emerging
preclinical and epidemiologic data, we propose that preg-
nant and postpartum cases be researched as distinct subsets
of PABC to clarify the risk imparted by pregnancy and the
events subsequent to pregnancy, such as breast involution,
on breast cancer. Further, we highlight the importance of
postpartum breast cancer as an area for further research to
reduce the increased metastatic potential and mortality of
PABC.
Keywords Pregnancy-associated breast cancer 
Young women’s breast cancer  Postpartum breast cancer 
Survival  Metastasis
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Breast cancer is the leading US cancer diagnosis in women
age 20–45 and is the leading malignancy diagnosed in
association with pregnancy in the US [1–3]. Pregnancy
results in a complex ‘‘‘dual effect’’ on breast cancer risk [4]
with a transient increased risk of breast cancer diagnosis
observed during the subsequent postpartum years for all
first time mothers [5–7]. This increased risk is reported to
last up to 15 years after childbirth regardless of the
mother’s age [5]. For women who are under 35 years at
first birth, a ‘‘cross-over’’ effect eventually begins to pro-
vide long-term protection against breast cancer [8–10].
Thus, the effect of a prior pregnancy on the risk for a young
women’s breast cancer risk is complex, from initial pro-
motion in the postpartum period to one of protection years
to decades later.
A pregnancy-associated breast cancer (PABC) is a
breast cancer diagnosed during or a few years subsequent
to a recent pregnancy. The specific definition of PABC has
varied throughout the literature and this variability in
defining PABC has led to conflicting results on the rela-
tionship between pregnancy, prior pregnancy and breast
cancer outcomes. PABC is often limited to breast cancer
diagnosed during pregnancy or within one-year postpartum
[1, 11–16]. A number of studies using this definition
demonstrate PABC as having inferior prognosis [1, 15, 16,
18, 21], while two studies identify no increased mortality
[11, 12]. Conversely, five large epidemiologic studies
specifically isolating postpartum breast cancers uniformly
report poor maternal outcomes associated with postpartum
PABC [22–26]. A recently published meta-analysis of 30
PABC studies further suggest that mothers diagnosed
postpartum have a significantly worse overall survival (OS)
(pHR 1.84, 95 % CI: 1.2–2.65) compared to non-PABC
breast cancer cases [21]. Thus, when PABC is defined as
combined pregnant and early postpartum cases, the epi-
demiologic data on maternal prognosis is inconsistent.
However, when cases diagnosed postpartum are examined
separately from cases diagnosed during pregnancy, the data
demonstrate an increased and potentially prolonged
maternal risk of poor outcomes, suggesting an expanded
definition of PABC is warranted.
The convention of limiting PABC to pregnant and early
postpartum diagnoses originated from studies demonstrat-
ing tumor growth promotion by hormonal milieus similar
to those occurring during pregnancy [10, 27, 28]. However,
in preclinical models, we reported that during normal,
postpartum mammary gland involution, the process where
the tissue remodels from a lactation competent to a non-
lactational state, the gland acquires several attributes in
common with wound-healing and tumor desmoplastic
microenvironments [29]. Furthermore, we have demon-
strated that postpartum involution increases the metastatic
potential of human tumor cells in xenograft models of
postpartum breast cancer [30]. Based on these observa-
tions, we proposed that postpartum involution is a unique
biologic event, separate from the effects of pregnancy, that
may contribute to the poor prognosis of postpartum breast
cancer [30].
In this study, we characterized young women’s breast
cancer by luminal A, luminal B, Her2 neu positive, and
triple negative biologic subtypes and other clincopatho-
logic features. In addition, we examined the association of
distant recurrence (DR) and OS with time since last child
birth to delineate the relationship between a postpartum
diagnosis and maternal prognosis.
Methods
A retrospective cohort study was conducted with 619
women age B45 years diagnosed with breast cancer during
1981–2011 at University of Colorado Hospital (n = 539)
and The Shaw Cancer Center in Edwards, CO (n = 80).
Patient data were abstracted through medical chart review.
71 % of cases are self-reported Caucasian (n = 440), 9 %
Hispanic (n = 56), 4.5 % Black (n = 28), and 3.7 % other
(n = 23). 11.8 % (n = 72) chose not to report racial
demographic information. All research was approved by
the Colorado Multiple Institutional Review Board.
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Defining cases by parity status
Postpartum breast cancer was defined as cancers diagnosed
within five years of a woman’s last childbirth (PABC \5,
n = 136), and those diagnosed during pregnancy were
considered a separate subset of PABC (n = 24). All cases
in the pregnant subset completed delivery of the co-diag-
nosed child. Later parous cases were combined according
to years between last childbirth and breast cancer diagno-
sis: parous[5—\10 (n = 130) and parous C10 (n = 147).
Nulliparous women with no evidence of previous preg-
nancy were used as the referent population (n = 125).
Nulliparous women with evidence of incomplete preg-
nancy were excluded (n = 57).
Clinical characterization of young women breast cancer
Cases were characterized according to parity grouping
(n = 562). Clinical stage was defined according to the
AJCC Cancer Staging Manual (7th Edition). Luminal A
biologic subtype was defined as ER?, PR?, Her2 neu
negative; luminal B defined as ER?, PR±, Her2 neu?;
Her2 neu? defined by ER-, PR-, Her2 neu?; and a triple
negative defined by ER, PR and Her2 neu all negative .
Statistical analysis
Cohort demographic, clinical, and treatment data are
summarized in Table 1. To test for intergroup differences,
Chi-square and Fishers Exact Test (categorical variables),
and One-Way ANOVA (continuous variables) were used.
Estimating risk of distant recurrence (DR) and overall
survival (OS)
A DR was defined as the presentation of breast cancer
metastasis following completed primary breast cancer stag-
ing. Cases with no evidence of DR and cases alive at the end
of followup were censored at the date of last contact. To
better power our analysis, cases diagnosed C5 years fol-
lowing last childbirth were collapsed. Nulliparous cases with
evidence of prior pregnancy (n = 57) and pregnant cases
(n = 24) were excluded from the outcomes analyses. Kap-
lan–Meier curves were created to determined crude differ-
ences in DR and OS. Cox proportional multivariate
regression models were performed to obtain adjusted risk
estimates for DR, OS, hazard ratios and 95 % confidence
intervals. Cases missing followup data (n = 52), model
covariates (n = 189), declining treatment (n = 4), or having
multiple primary breast cancers (n = 6), and cases stage 0
(n = 15) and stage IV (n = 27) were excluded. After these
exclusions, 326 cases were analyzed for DR. Stage IV cases
were included in the OS analysis to reflect true population
outcomes, resulting in 334 cases available for the OS anal-
ysis. Stage, biologic subtype, prior local recurrence, and year
of diagnosis were included in the final multivariate model of
DR. Stage, biologic subtype, and year of diagnosis were
included in the final multivariate model of OS. Age at
diagnosis was not significantly different between groups and
was not included in the multivariate models.
All statistics were performed using SAS 9.2. A p value
of B0.05 was considered statistically significant.
Results
Table 1 shows the clinical characterization of our Colorado
young women’s breast cancer cohort. We did not observe a
significant difference in histologic subtype across parity
groups (p = 0.09). While there was a slightly higher fre-
quency of lobular carcinoma in all parous groups compared
to nulliparous, this result was not significant. Similarly, we
did not detect a significant difference in histologic grade
(p = 0.27), tumor size (p = 0.18), clinical stage (p = 0.40),
or nodal involvement (p = 0.45) between parity groups.
While all postpartum groups demonstrated an increased
frequency of lymphovascular invasion compared to nullip-
arous, these differences were not significant. We did not
observe differences in chemotherapy and radiation treat-
ment modalities between parity groups. However, compared
to PABC\5 cases, nulliparous cases more often underwent
breast conservation therapy (22.9 vs. 46.8 %), while PABC
\5 cases received mastectomy more frequently compared to
nulliparous cases (p \ 0.0001) (Table 1).
To evaluate the effect of prior pregnancy on maternal
outcomes, we examined the risk of DR and OS. Postpartum
PABC cases demonstrated a higher five-year DR proba-
bility (31.1 %) compared to nulliparous cases (14.8 %)
(Fig. 1a, b) and had a significant 2.8 times higher risk of
DR (HR 2.80, 95 % CI: 1.12–6.57) compared to nullipa-
rous cases (Table 2). The multivariate DR risk model
demonstrated an increased metastatic potential associated
with a breast cancer diagnosed within five-years post-
partum, adjusting for stage at diagnosis, biologic subtype,
prior local recurrence, and year of diagnosis.
PABC \5 cases demonstrated a crude lower five-year
OS probability (65.8 %) compared to nulliparous cases
(98.0 %) (Fig. 1c, d). The relatively high five-year OS in
this nulliparous cohort mirrors previously published data
[18]. After adjusting for stage, biologic subtype, and year
of diagnosis, PABC \5 cases had a significant 2.7 times
greater risk of death compared to nulliparous cases (HR
2.65, 95 % CI: 1.09–6.42) (Table 3).
To evaluate clinical outcomes for cases diagnosed
C5-years postpartum, we compressed later parity cohorts to
increase statistical power (Supplemental Table 8). Our data
Breast Cancer Res Treat (2013) 138:549–559 551
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Table 1 Clinical Characterization of UC Young Women’s Breast Cancer Cohort
Parity group Nulliparous PABC \5 Parous C5 —\10 Parous C10 p value
(N = 125) (N = 136) (N = 130) (N = 147) Overall PABC \5 vs.
nulliparousNo. (%) No. (%) No. (%) No. (%)
Mean age at diagnosis 37.3 ± 5.5 35.7 ± 5.3 38.7 ± 4.5 40.9 ± 3.5 \0.0001d \0.05d
Histologic subtype
Ductal 109 (87.20) 120 (88.24) 111 (85.38) 119 (80.95) 0.09e 0.54e
12 (8.16)Lobular 1 (0.80) 5 (3.68) 10 (7.69)
Ductal ? lobular 3 (2.40) 3 (2.21) 5 (3.85) 6 (4.08)
Inflammatory 2 (1.60) 2 (1.47) 1 (0.77) 5 (3.40)
Other 5 (4.00) 4 (2.94) 1 (0.77) 2 (1.36)
Missing 5 (4.00) 2 (1.47) 2 (1.54) 3 (2.04)
Biologic subtype
Luminal A 38 (30.40) 52 (38.24) 47 (36.15) 49 (33.33) 0.96f 0.78f
Luminal B 18 (14.40) 17 (12.50) 13 (10.00) 18 (12.24)
Her2 neu positive 11 (8.80) 11 (8.09) 12 (9.23) 13 (8.84)
Triple negative 18 (14.4) 20 (14.71) 16 (12.31) 25 (17.01)
Missing Her2 neua 28 (22.40) 28 (20.59) 26 (20.00) 32 (21.77)
Missing ER or PR 12 (9.60) 8 (5.88) 16 (12.30) 10 (6.80)
Estrogen status
ER? 77 (61.6) 87 (63.9) 81 (62.3) 83 (56.46) 0.37f 0.48f
ER- 39 (31.2) 37 (27.20) 39 (30.0) 54 (36.73)
Missing 9 (7.2) 10 (7.35) 10 (7.69) 10 (6.80)
Histologic grade
Grade I 15 (12.00) 10 (7.35) 14 (10.77) 18 (12.24) 0.27f 0.55f
Grade II 39 (31.20) 39 (28.68) 39 (30.00) 60 (40.82)
Grade III 61 (48.80) 73 (53.68) 63 (48.46) 54 (36.73)
Missing 10 (8.00) 14 (10.29) 14 (10.77) 15 (10.20)
Tumor size
0.1—B2.0 cm 61 (48.80) 67 (49.26) 49 (37.69) 62 (42.18) 0.18f 0.97f
[2.0—B5.0 cm 41 (32.80) 44 (32.35) 45 (34.62) 59 (40.14)
[5.0 cm 14 (11.20) 14 (10.29) 25 (19.23) 20 (13.60)
Missing 9 (7.20) 11 (8.09) 11 (8.46) 6 (4.08)
Stage
0 4 (3.20) 3 (2.21) 5 (3.85) 3 (2.04) 0.40f 0.62f
I 36 (28.80) 34 (25.00) 27 (20.77) 39 (26.53)
II 52 (41.60) 52 (38.24) 57 (43.85) 62 (42.18)
III 20 (16.00) 26 (19.12) 31 (23.85) 31 (21.09)
IV 6 (4.80) 12 (8.82) 2 (1.54) 7 (4.76)
Missing 7 (5.60) 9 (6.62) 8 (6.15) 5 (3.40)
Lymph node involvement
Positive 59 (47.20) 76 (55.88) 64 (49.23) 71 (48.30) 0.45f 0.14f
Negative 64 (51.20) 57 (41.91) 65 (50.00) 72 (48.98)
Missing 2 (1.60) 3 (2.21) 1 (0.77) 4 (2.72)
Lymphovascular invasion
Present 28 (22.40) 40 (29.41) 40 (30.77) 57 (38.78) 0.21f 0.15f
Absent 55 (44.00) 50 (36.76) 53 (40.77) 60 (40.82)
Missing 42 (33.60) 46 (33.82) 37 (28.46) 30 (20.41)
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suggest that cases diagnosed C5-years postpartum may have
a prognosis intermediate to PABC\5 and nulliparous cases
(Fig. 1a–d). These cases demonstrated a crude 19.9 % five-
year DR probability and crude 77.5 % five-year OS proba-
bility. Cases diagnosed C5 had a significantly lower DR risk
compared to PABC\5 cases (HR 0.36; 95 % CI: 0.18–0.75)
(Table 2). However, compared to nulliparous cases, cases
C5 postpartum showed a trend toward higher risk of death
(HR 1.52; 95 % CI: 0.71–3.28), but this result did not meet
significance (Table 3). Age at diagnosis was examined as
both a continuous and categorical variable (\35 or C35, or
\40 or C40) in the univariate DR and OS models, but did
not reach statistical criterion for inclusion in the final mod-
els. Hazard ratios for the final multivariate models are
included in the supplemental material (Table 6, Table 7).
To investigate whether PABC may be two distinct sub-
sets, based on patient outcomes, we combined cases based
on previously published definitions [1, 11, 12, 15, 16, 18],
and grouped pregnant cases and cases diagnosed B1 year
postpartum as in the ‘‘PABC group.’’ Nulliparous and/or
parous women diagnosed [1 year postpartum were com-
bined to comprise the ‘‘non-PABC’’ controls, mirroring
methods used in two recent studies reporting negative results
[11, 12]. When grouped this way, we also did not observe a
significant difference in OS between ‘‘PABC’’ and ‘‘non-
PABC’’ cases (Table 4). To examine if the poor prognosis
observed in our PABC \5 cohort is driven by cases diag-
nosed early postpartum (B1), we examined the adjusted OS
in postpartum B1 compared to postpartum[1—5. We did
not observe a significantly lower OS in postpartum cases B1
compared to the later postpartum cases (p = 0.51). Further,
when we examined the crude number of deaths broken down
by years postpartum at diagnosis [B1, [1—B2, [2—B3,
[3—B4, and[4—B5 years], we did not observe a skew-
ing of deaths to the earlier postpartum time points
(Fig. 2).
Cases diagnosed during pregnancy showed a high fre-
quency of ductal carcinoma (91.7 %) and poorly differ-
entiated tumors (70.8 %). Over half of these pregnant cases
had involved lymph nodes (62.5 %) and 42 % were diag-
nosed with late stage disease. Luminal A (20 %), Luminal
B (20 %), Her2 neu? (20 %), and triple negative (25 %)
biologic subtypes were present in almost equal frequencies
(Table 5). However, due to the small number of pregnant
Table 1 continued
Parity group Nulliparous PABC \5 Parous C5 —\10 Parous C10 p value
(N = 125) (N = 136) (N = 130) (N = 147) Overall PABC \5 vs.
nulliparousNo. (%) No. (%) No. (%) No. (%)
Surgery typeb
No surgery 0 (0) 3 (2.5) 1 (0.88) 3 (2.3) \0.0001f \0.0001f
Local excisionc 0 (0) 0 (0) 1 (0.88) 1 (0.8)
Lumpectomy 51 (46.8) 27 (22.9) 32 (28.0) 36 (28.1)
Unilateral mastectomy 25 (22.9) 37 (31.4) 48 (42.1) 51 (39.8)
Bilateral mastectomy 15 (13.8) 37 (31.4) 17 (14.9) 11 (8.6)
Missing 18 (16.5) 14 (11.8) 15 (13.2) 26 (20.3)
Chemotherapyb
Yes 66 (60.6) 79 (67.0) 71 (62.3) 71 (55.5) 0.55f 0.17f
No 22 (20.2) 16 (13.6) 21 (18.4) 22 (17.2)
Missing 21 (19.2) 23 (19.4) 22 (19.3) 35(27.3)
Radiation therapyb
Yes 57 (52.2) 51 (43.2) 61 (53.5) 50 (39.0) 0.07f 0.22f
No 29 (26.6) 38 (32.2) 26 (22.8) 44 (34.4)
Missing 23 (21.1) 29 (24.6) 27 (23.7) 34 (26.6)
a Missing Her2 neu data, reflecting unavailable Her2 neu staining or FISH analysis at diagnosis, was evenly distributed across parity groups and
thus is not anticipated to confound results
b Treatment data for cases diagnosed at the University of Colorado Hospital (n = 469)—nulliparous (n = 109), PABC \5 (N=118), Parous
C5—\10 (n = 114); Parous C10 (n = 128). Treatment data unavailable for cases diagnosed at The Shaw Cancer Center (n = 80); treatment
data for cases diagnosed during pregnancy are included in supplemental Table 7
c Primary unknown
d One Way Anova with Tukey’s Multiple Comparisons Test
e Fisher’s Exact Test
f v2 Test
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cases (n = 24), we did not test for a significant enrichment
in these clinical characteristics over non-pregnant cases.
Further, due to the small sample size and short followup
time, we did not analyze maternal outcomes specific to
diagnosis during pregnancy.
In summary, these data demonstrate poor prognosis in
breast cancer patients diagnosed within five years of a
pregnancy and suggest an intermediate risk in women
diagnosed beyond five-years postpartum. When we apply
these definitions to this Colorado cohort, we identify of a
large subset (29 %) of young breast cancer cases with a
potential high risk of DR and death due to recent pregnancy
(postpartum \5 years) (Fig. 3).
Discussion
Our results demonstrate that a breast cancer diagnosed
within five-years postpartum has a significant 2.8 times
higher risk for metastasis and a 2.7 times higher mortality
risk compared to nulliparous cases. Our data further shows
that a postpartum breast cancer diagnosis is an independent
risk factor for recurrence and death. In our cohort, the
increased risk of death imparted by a postpartum diagnosis
was higher when compared with previous published studies
[22–24, 26, 31]. A strength of our study is the ability to
include clinical and pathologic characteristics known to
affect prognosis into our adjusted outcomes analysis for the



































































































































Years Post Diagnosis Years Post Diagnosis
(a) (b)
(c) (d)
Fig. 1 a Unadjusted probability
of distant recurrence in PABC
\5, C5, and nulliparous cases
demonstrates an increased risk
of distant recurrence in
postpartum PABC. b Adjusted
probability of distance
recurrence in PABC \5, C5,
and nulliparous cases adjusted
for biologic subtype, clinical
stage, year of diagnosis, and
local recurrence. The adjusted
recurrence probability function
based on the Cox model was
generated for each subject.
c Unadjusted overall survival
probability in PABC \5, C5
and nulliparous cases
demonstrates an increased risk
of death in postpartum PABC.
d Adjusted overall survival
probability in PABC \5, C5,
and nulliparous cases adjusted
for biologic subtype, clinical
stage, and year of diagnosis.
The adjusted survival function
based on the Cox model was
generated for each subject
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effect of pregnancy on recurrence and death. As such, one
potential reason for our higher risk differences may be the
absence of clinical characteristics in prior PABC studies
and thus the inability to report adjusted risk estimates [23,
26, 31].
In our cohort, parous women diagnosed C5 years fol-
lowing last childbirth trended toward a prognosis inter-
mediate to PABC\5 and nulliparous women. We propose
that the period of postpartum risk may persist to at least
five-years postpartum as demonstrated by these data, which
are likewise supported by previously published studies
highlighting the postpartum window of risk [22–26, 31]. In
two of these population-based studies, poor outcomes were
observed in women diagnosed up to eight years after
childbirth [23], as well as a recent study demonstrated peak
mortality in women diagnosed postpartum and persisting
Table 2 Adjusted risk estimates of distant recurrence
Multivariate analysis
Parity groupa Number of cases Adjusted HRb,c 95 % CI p 5-Year distant recurrence
probability (%)
PABC \5 N = 84 2.80 1.12–6.57 0.02 31.3
Parous C5 N = 168 1.01 0.48–2.15 0.97 19.9
Nulliparous N = 74 1.0 – – 14.8
Hazard ratios and 95 % confidence intervals for all covariates included in the final model are described in Table 6 in the supplemental material.
Clinical characteristics of the collapsed Parous C5 group can be viewed in Table 8 in the supplemental material
Parous C5, cases diagnosed five years or later from last childbirth
a PABC\5 cases had a mean followup time of 2.7 ± 2.7 years. Mean followup time for nulliparous was 3.2 ± 3.2 years and 3.5 ± 3.6 years for
cases diagnosed C5
b Adjusted for tumor biologic subtype, clinical stage, year of diagnosis, and local recurrence
c Histologic subtype and grade were not univariately significant and were thus not included in the final multivariate models
Table 3 Adjusted risk estimates of overall survival
Multivariate analysis
Parity groupa Number of cases Adjusted HRb,c 95 % CI p 5-Year survival (%)
PABC \5 N = 86 2.65 1.09–6.42 0.03 65.8
Parous C5 N = 172 1.52 0.71–3.28 0.28 77.5
Nulliparous N = 76 1.0 – – 98.0
Hazard ratios and 95 % confidence intervals for all covariates included in the final model are described in Table 7 in the supplemental material.
Clinical characteristics of the collapsed Parous C5 group can be viewed in Table 8 in the supplemental material
Parous C5 cases diagnosed five years or later from last childbirth
a PABC\5 cases had a mean followup time of 3.0 ± 2.9 years. Mean followup time for nulliparous was 3.6 ± 3.6 years and 3.9 ± 3.7 years for
cases diagnosed C5
b Adjusted for tumor biologic subtype, clinical stage, and year of diagnosis
c Histologic subtype and grade were not univariately significant and were thus not included in the final multivariate models
Table 4 Adjusted risk estimate of overall survival using published definitions of PABC and control cohorts
Parity group Adjusted HRa 95 % CI p
PABC B1 (n = 33) 0.78 0.29–2.11 0.63
Non-PABC (A) (n = 318) 1.0 – –
PABC B1 (n = 33) 0.77 0.28–2.08 0.60
Non-PABC (B) (n = 242) 1.0 – –
PABC B1, cases diagnosed during pregnancy or up to one-year postpartum; Non-PABC (A), nulliparous cases and parous cases diagnosed
[1 year from last childbirth. Non-PABC (B) ,parous cases diagnosed [1 year from last childbirth (nulliparous excluded)
a Adjusted for tumor biologic subtype, clinical stage and year of diagnosis
Breast Cancer Res Treat (2013) 138:549–559 555
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up to 10-years post-diagnosis [26]. We intentionally looked
at our data by individual number of years postpartum to
identify if an early ‘‘cutoff’’ of increased risk existed and
found that the postpartum risk of recurrence and death is
not limited to the first or second-year postpartum, as some
studies previously suggested [1, 15, 16, 18]. At present, we
cannot delineate the exact outer limit of this postpartum
timeframe which may influence poor maternal prognosis.
However, further study in larger cohorts with complete
clinical data is necessary to better define the true extent and
clinical implications of this interaction between postpartum
diagnosis and increased risk of breast cancer recurrence
and death.
Another aim of our study was to identify a methodo-
logical reason for the disparate results in prior PABC
studies. An important distinction of our study is the utili-
zation of rigorously defined parity status. Prior studies have
combined pregnant and early postpartum cases as PABC
and utilized various referent populations. Six published
studies reporting outcomes included parous women diag-
nosed within seven to 24 months of last childbirth in the
non-PABC ‘‘control’’ group—four studies identify an
increased risk for PABC cases [1, 15, 16, 18] and two
report no increase in risk [11, 12]. Of the four studies
identifying an increased risk for PABC cases, three used a
PABC cohort comprised of predominately early post-
partum cases [1, 15, 18]. One study used a PABC cohort
comprised of 40 % early postpartum and 60 % pregnant
cases [16].When we applied similar definitions of PABC
[pregnant and up to 1 year postpartum] and non-PABC
[nulliparous and beyond 1 year postpartum] to our cohort,
we also did not observed a significant increased risk
associated with PABC (Table 4). We believe the inclusion
of high-risk postpartum cases in the non-PABC control
population blurs the true risk associated with a postpartum
and nulliparous diagnosis. While our numbers of combined
pregnant and \1 year postpartum are small, we provide
evidence for the first time that the definition of the PABC
and the nulliparous groups may obscure the risk of
metastasis and death in postpartum breast cancer.
Currently, it is challenging to explain the conflicting
data provided by these numerous studies to clarify the
potential individual contributions of the pregnant and
postpartum settings on breast cancer outcomes. Studies
with pregnancy-specific data often include cases defini-
tively treated during pregnancy, cases with early trimester
terminations, and cases diagnosed during pregnancy, but
treated postpartum [12, 18, 32] within the pregnant cohort.
Person-Years Contributed 
Fig. 2 Crude mortality broken out into years between last childbirth
and breast cancer diagnosis shows increased risk continues 3–5 years
postpartum
Table 5 Clinical characteristics
of cases diagnosed during







Grade I 0 (0)
Grade II 5 (20.8)













Luminal A 5 (20.80)
Luminal B 5 (20.80)
Her2 neu positive 5 (20.80)







0.1—B2.0 cm 9 (37.50)
[2.0—B5.0 cm 9 (37.50)
[5.0 cm 3 (12.50)
Missing 3 (12.50)
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The impact of these clinical factors on breast cancer out-
comes for women diagnosed during pregnancy is unknown.
Furthermore, studies examining pregnant cases treated with
definitive intent during pregnancy and concomitant main-
tenance of the pregnancy demonstrate equivalent outcomes
to age-matched, stage-matched, non-pregnant controls [33,
34]. Our pregnancy cohort all completed delivery and
received surgery and/or chemotherapy during pregnancy.
We report a higher percentage of Her2 neu and triple
negative cases over other subtypes which are unique to
cases diagnosed during pregnancy (Table 5). A similar
increase of triple negative associated with diagnosis during
pregnancy was recently reported [17]. However, the size of
our pregnant cohort does not permit further characteriza-
tion, conclusions, or outcomes investigation at this time.
Currently, others are making important efforts to build a
large pregnant breast cancer registry to provide the
resources necessary to help address these questions [2].
Our observation of equal presentation of biologic sub-
types between nulliparous, PABC \5, and later parous
cases contrasts prior reports [1, 12, 13, 16, 17] and may
reflect underlying differences in sociodemographic and
lifestyle factors in this dominantly Caucasian, single-state
cohort. Importantly, it may also reflect a difference in
outcomes depending on the definition of PABC. Previous
studies that reported on combined pregnant and early
postpartum cancers found an ‘‘aggressive phenotype,’’
characterized by advanced clinical stage, larger tumor size,
increased nodal involvement, and higher histologic grade
[1, 11, 12, 16]. Moreover, compared to non-PABC cases,
various studies reported these combined pregnant and early
postpartum tumors are marked by reduced estrogen and
progesterone receptor positivity [1, 12, 13, 16], as well as
higher frequency of Her2 neu positivity but not specifically
the triple negative subtype [13, 17]. When early postpartum
and pregnant cases were evaluated independently, there
was contradictory data reported on the clinicopathologic
features of these pregnant and postpartum subsets [12, 13,
17–20]. Moreover, a recent PABC publication concluded
triple negative tumors were more likely to be diagnosed
within two-years postpartum [17]. However, in that study,
when the pregnant (n = 8) cases were separated from the
exclusively postpartum cases (n = 30), there was no
association of triple negative tumors with a postpartum
diagnosis [17]. In summary, we believe it is important to
recognize that the characteristics of breast cancers diag-
nosed during pregnancy or postpartum may differ based on
PABC definition, as well as due to potential confounders
such as race or size of the cohort. The causal relationships
between concurrent or prior pregnancy and tumor charac-
teristics at diagnosis are not fully understood and beyond
the scope of this report. However, as our data demonstrate,
tumor characteristics alone do not account for the poorer
prognosis of postpartum breast cancer and identification of
the drivers for this increased risk of postpartum breast
cancers are necessary to improve clinical outcomes.
To our knowledge, our study is unique in providing a
contemporary comparison of outcomes between exclu-
sively nulliparous and postpartum young women’s breast
cancer cohorts. The favorable outcomes of our nulliparous
group, compared to prior studies with similar cohorts, may
reflect a period effect as breast cancer treatment has
improved significantly over time [24, 31, 32]. Our data
demonstrate a striking 2.7 higher risk of death for women
diagnosed within five-years postpartum compared to nul-
liparous, after adjusting for biologic subtype, clinical stage,
and year of diagnosis. Our research program has identified
postpartum breast involution as being promotional to tumor
growth, invasion, and metastasis in preclinical models [30].
Similar tumor promotional attributes have been identified
in human breast involution [30, 35], as recently reviewed
[36]. Therefore, we hypothesized that human postpartum
breast cancer has poorer prognosis that is not solely
explained by an enrichment of traditional poor prognostic
factors that are tumor cell centric [8, 10, 30, 35]. While our
results do not definitively prove the role of involution as
etiologic for poorer postpartum outcomes, it does support
the potential that breast involution imparts a unique tumor
microenvironment as a mechanism for this increased risk
[8, 36]. Further research in human cohorts on the interac-
tion of pregnancy and subsequent breast cancer will need to
include additional potential confounders, such as diversi-
fication of race, number of prior pregnancies with age at
first pregnancy and intervals between, lactation data, gene
mutation status, and detailed family history.
The under recognition of PABC and its impact on
maternal outcomes is likely an unintended consequence of
the variable definitions of the disease and the conflicting
outcomes data. We demonstrate that limiting the definition
Fig. 3 Expanding the definition of PABC as cases diagnosed within
five-years postpartum, we demonstrate 29 % of cases have an
increased risk for poor prognosis. Only 10 % are considered PABC
when defined as cases pregnant and postpartum up to one year
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of PABC as cases diagnosed during or within one year of a
completed pregnancy translate into a low PABC incidence
(10 %) in our Colorado cohort. Expanding the definition of
PABC to within five-years postpartum increases this inci-
dence to 29 % for women diagnosed B45 years. This
higher PABC incidence is substantiated in a recently
published study of young women’s breast cancer where
35 % of cases were diagnosed within five-years postpartum
[17]. In addition, PABC incidence could be as high as
53.0 % or more of young women’s breast cancer if the
trend in later parous groups (C5 and \10 years post-
partum) becomes significant in analyses of larger cohorts
with longer followup (Fig. 3). If the distribution of post-
partum PABC in our cohort is nationally representative,
over a five-year period we would expect approximately
34,000 incident invasive breast cancer cases attributable to
high risk postpartum PABC (PABC \5), and 6,900 inci-
dent diagnoses annually [37, 38].
Pregnancy ubiquitously proceeds involution and has its
own significant biologic programs that influence breast
cancers diagnosed both ante- and postpartum [8, 36]. Post-
partum breast involution is a biologically unique event that
is also emerging as a potential risk factor for premenopausal
breast cancer [8, 30, 36]. Understanding the differences
between breast cancers diagnosed during pregnancy and
postpartum would better permit the translation of informa-
tive data from basic science and epidemiologic studies into
the clinical care of young women’s breast cancer. Therefore,
we propose defining PABC as two distinct subsets—cases
diagnosed during pregnancy and cases diagnosed post-
partum—to facilitate clarity in the PABC field.
Acknowledgments We thank Betsy Risendall, PhD, Assistant
Research Professor, Department of Community and Behavior Health,
The Colorado School of Public Health, University of Colorado
Cancer Center, University of Colorado Denver Anschutz Medical
Campus, and Anna E. Baron, PhD, Professor, Department of Com-
munity and Behavior Health, Department of Biostatistics and Infor-
matics, The Colorado School of Public Health, University of
Colorado Denver Anschutz Medical Campus, for Design and conduct
of the study. We also thank Amy Kendall, CTR, Lead Medical
Registrar, Cancer Registry, University of Colorado Hospital, for her
help in Data collection and Ann D. Thor, MD, Department Chair,
Department of Pathology, University of Colorado Denver Anschutz
Medical Campus, for Research Assistant support.
Funding/Support Department of Defense BC060531 to Pepper
Schedin and Virginia Borges, AACR-BCRF 09-60-26 to Virginia
Borges, Avon Foundation to Pepper Schedin, Men for the Cure
Foundation to Virginia Borges, and ACS 116056-PF-08-257-01-CSM
to Traci Lyons, Grohne Family Foundation Grant to Virginia Borges
and Pepper Schedin, and Glass Family Foundation to Virginia Borges.
Conflict of interest The authors declare that they have no conflict
of interest.
Ethical standards Conduct of this study at the University of Col-
orado Hospital and the Shaw Cancer Center was performed in
compliance with the standards of the Colorado Research Ethics Board
(COMIRB).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Rodriguez AO et al (2008) Evidence of poorer survival in preg-
nancy-associated breast cancer. Obstet Gynecol 112(1):71–78
2. Cardonick E et al (2010) Breast cancer during pregnancy:
maternal and fetal outcomes. Cancer J 16(1):76–82
3. Pregnancy and Breast Cancer (2011); Available from: http://www.
cancer.org/Cancer/BreastCancer/MoreInformation/pregnancy-and-
breast-cancer. Accessed 12 May 2011
4. Janerich DT, Hoff MB (1982) Evidence for a crossover in breast
cancer risk factors. Am J Epidemiol 116(5):737–742
5. Lambe M et al (1994) Transient increase in the risk of breast
cancer after giving birth. N Engl J Med 331(1):5–9
6. Lord SJ et al (2008) Breast cancer risk and hormone receptor
status in older women by parity, age of first birth, and breast-
feeding: a case-control study. Cancer Epidemiol Biomarkers Prev
17(7):1723–1730
7. Liu Q et al (2002) Transient increase in breast cancer risk after
giving birth: postpartum period with the highest risk (Sweden).
Cancer Causes Control 13(4):299–305
8. Lyons TR, Schedin PJ, Borges VF (2009) Pregnancy and breast
cancer: when they collide. J Mammary Gland Biol Neoplasia
14(2):87–98
9. Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence
mathematical model of breast cancer incidence. J Natl Cancer
Inst 88(6):359–364
10. Schedin P (2006) Pregnancy-associated breast cancer and
metastasis. Nat Rev Cancer 6(4):281–291
11. Murphy CG et al (2011) Current or recent pregnancy is associated
with adverse pathologic features but not impaired survival in
early breast cancer. Cancer 118(13):3254–3259
12. Beadle BM et al (2009) The impact of pregnancy on breast cancer
outcomes in women \ or = 35 years. Cancer 115(6):1174–1184
13. Genin AS et al (2012) Pregnancy-associated breast cancers: do
they differ from other breast cancers in young women? Breast
21(4):550–555
14. Petrek JA, Dukoff R, Rogatko A (1991) Prognosis of pregnancy-
associated breast cancer. Cancer 67(4):869–872
15. Ali SA et al (2012) Survival outcomes in pregnancy associated breast
cancer: a retrospective case control study. Breast J 18(2):139–144
16. Bonnier P et al (1997) Influence of pregnancy on the outcome of
breast cancer: a case-control study. Societe Francaise de Senol-
ogie et de Pathologie Mammaire Study Group. Int J Cancer
72(5):720–727
17. Pilewskie M et al (2011) Association between recency of last
pregnancy and biologic subtype of breast cancer. Ann Surg Oncol
19(4):1167–1173
18. Mathelin C et al (2008) Pregnancy and post-partum breast cancer:
a prospective study. Anticancer Res 28(4C):2447–2452
19. Gentilini O et al (2005) Breast cancer diagnosed during preg-
nancy and lactation: biological features and treatment options.
Eur J Surg Oncol 31(3):232–236
20. Reed W et al (2003) Pregnancy and breast cancer: a population-
based study. Virchows Arch 443(1):44–50
21. Azim HA Jr et al (2012) Prognosis of pregnancy-associated
breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev
38(7):834–842
558 Breast Cancer Res Treat (2013) 138:549–559
123
22. Dodds L et al (2008) Relationship of time since childbirth and
other pregnancy factors to premenopausal breast cancer progno-
sis. Obstet Gynecol 111(5):1167–1173
23. Bladstrom A, Anderson H, Olsson H (2003) Worse survival in
breast cancer among women with recent childbirth: results from a
Swedish population-based register study. Clin Breast Cancer
4(4):280–285
24. Whiteman MK et al (2004) Reproductive history and mortality
after breast cancer diagnosis. Obstet Gynecol 104(1):146–154
25. Stensheim H et al (2009) Cause-specific survival for women
diagnosed with cancer during pregnancy or lactation: a registry-
based cohort study. J Clin Oncol 27(1):45–51
26. Johansson AL et al (2011) Increased mortality in women with
breast cancer detected during pregnancy and different periods
postpartum. Cancer Epidemiol Biomarkers Prev 20(9):1865–1872
27. Pike MC et al (1983) ‘Hormonal’ risk factors, ‘breast tissue age’
and the age-incidence of breast cancer. Nature 303(5920):767–770
28. Keller KB, Lemberg L (2005) Estrogen plus progestin, benefits
and risks: the ‘‘Women’s Health Initiative’’ trials. Am J Crit Care
14(2):157–160
29. McDaniel SM et al (2006) Remodeling of the mammary micro-
environment after lactation promotes breast tumor cell metastasis.
Am J Pathol 168(2):608–620
30. Lyons TR et al (2011) Postpartum mammary gland involution
drives progression of ductal carcinoma in situ through collagen
and COX-2. Nat Med 17(9):1109–1115
31. Daling JR et al (2002) The relation of reproductive factors to
mortality from breast cancer. Cancer Epidemiol Biomarkers Prev
11(3):235–241
32. Guinee VF et al (1994) Effect of pregnancy on prognosis for
young women with breast cancer. Lancet 343(8913):1587–1589
33. Garcia-Manero M et al (2009) Pregnancy associated breast can-
cer. Eur J Surg Oncol 35(2):215–218
34. Keleher AJ et al (2002) Multidisciplinary management of breast
cancer concurrent with pregnancy. J Am Coll Surg 194(1):54–64
35. O’Brien J et al (2010) Alternatively activated macrophages and
collagen remodeling characterize the postpartum involuting
mammary gland across species. Am J Pathol 176(3):1241–1255
36. Kobayashi S et al (2012) Reproductive history and breast cancer
risk. Breast Cancer 19(4):302–308
37. US Cancer Statistics: An interactive Atlas (2009). Available
from: http://apps.nccd.cdc.gov/DCPC_INCA/DCPC_INCA.aspx.
Accessed 13 Feb 2013
38. Proabablity of Breast Cancer in American Women (2012).
Available from: http://www.cancer.gov/cancertopics/factsheet/
detection/probability-breast-cancer. Accessed 13 Feb 2013
Breast Cancer Res Treat (2013) 138:549–559 559
123
